Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial DSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, ...

Shares of Ocugen OCGN declined 8.6% on Tuesday after the company announced 12-month data from the phase II ArMaDa study evaluating its novel modifier gene therapy, OCU410, for treating geographic ...

Please provide your email address to receive an email when new articles are posted on . The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a ...

Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support ...

Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American ...

Ocugen lines up key gene therapy catalysts through 2027, with pivotal data, filings, and milestones across three eye programs set to drive stock volatility.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There were no serious adverse events reported in the six ...